A crystal form of a neurokinin-1 antagonist and its preparation method

By preparing the A-crystal form of compound II, the problem of poor stability caused by amorphous structure was solved, and the chemical stability and flowability of the compound were improved, making it suitable for drug compositions for a variety of diseases.

CN114671913BActive Publication Date: 2026-11-17SHANGHAI SHENGDI PHARMA CO LTD +2
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202111594155.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-12-25
Filing Date
2021-12-24
Publication Date
2026-11-17
Estimated Expiration
2041-12-24

AI Technical Summary

Technical Problem

The existing amorphous structure of Formula II compounds leads to poor stability, difficulty in crystallization, and poor flowability, making it difficult to meet the needs of clinical applications.

Method used

The A-type of compound of formula II and its preparation method are provided. The crystal structure is confirmed by mixing with diethyl ether solvent and separating the solid, X-ray powder diffraction pattern and differential scanning calorimetry analysis, and conventional crystallization methods such as volatilization crystallization and cooling crystallization are combined to prepare the A-type with good stability.

Benefits of technology

The chemical stability and flowability of the Formula II compound have been improved, making it suitable for clinical applications and applicable to the preparation of pharmaceutical compositions for treating a variety of diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114671913B_ABST
    Figure CN114671913B_ABST
Patent Text Reader

Abstract

This disclosure relates to a crystal form of a neurokinin-1 antagonist and a method for its preparation. Specifically, this disclosure relates to the crystallization of compound A of formula II and its preparation method. The novel crystal form of this disclosure possesses favorable physicochemical properties, which is more beneficial for clinical treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This disclosure relates to a crystal form of a neurokinin-1 antagonist, specifically to the A crystal form of a compound of formula II and its preparation method. Background Technology

[0002] Tachykinins are peptide ligands of neurokinin receptors. Neurokinin receptors, such as NK1, NK2, and NK3, are involved in a variety of biological processes. They can be found in the nervous and circulatory systems of mammals, as well as in peripheral tissues. Therefore, the regulation of these receptors has been studied for the potential treatment or prevention of various physiological disorders, symptoms, or diseases in mammals.

[0003] On the other hand, drug-induced hemolysis is caused by the massive destruction of red blood cells due to immune factors after the drug enters the body, resulting in clinical manifestations such as anemia, jaundice, and hemolysis of urine. Drug-induced hemolytic anemia can be divided into the following three types: (1) drug-induced immunity, leading to antibody-mediated hemolytic reactions; (2) drugs acting on red blood cells with genetic enzyme defects (e.g., G6PD deficiency); and (3) drug-induced hemolytic reactions to abnormal hemoglobins. The key to treating this disease is to stop using the relevant drugs and control the occurrence of hemolysis to prevent complications.

[0004] PCT / CN2020 / 098460 discloses a novel NK1 antagonist prodrug compound (Formula II) that is effective in treating various physiological disorders, symptoms and diseases with minimal side effects and exhibits good pharmaceutical activity.

[0005]

[0006] The crystal structure of a pharmaceutical active ingredient often affects its chemical stability. Different crystallization and storage conditions can lead to changes in the crystal structure of the compound, sometimes even resulting in other crystal forms. Generally, amorphous drug products lack regular crystal structures and often have other defects, such as poor product stability, fine crystals, difficulty in filtration, easy agglomeration, and poor flowability. Therefore, it is essential to improve the properties of the compound shown in Formula II. We need to conduct in-depth research to find new crystal forms with high purity and good chemical stability. Summary of the Invention

[0007] This disclosure provides a crystal form A of the compound shown in Formula II, which has good stability and can be better applied in clinical practice.

[0008]

[0009] The A crystal form of the compound shown in Formula II provided in this disclosure has characteristic peaks in its X-ray powder diffraction pattern at 2θ angles of 10.336, 12.530, 17.987, 18.487, and 20.937.

[0010] The A crystal form of the compound shown in Formula II provided in this disclosure has characteristic peaks in its X-ray powder diffraction pattern at 2θ angles of 10.336, 11.705, 12.530, 16.848, 17.987, 18.487, 19.840, 20.937, 22.865, and 23.580.

[0011] The A-crystal form of the compound of formula II disclosed herein has an X-ray powder diffraction pattern at 2θ angles of 8.367, 10.336, 11.150, 11.705, 12.530, 13.306, 14.236, 15.252, 16.330, 16.848, 17.459, 17.987, 18.487, and 19.294. Characteristic peaks are observed at 19.840, 20.937, 21.963, 22.285, 22.865, 23.580, 24.812, 25.961, 26.798, 27.597, 28.761, 29.784, 31.737, 32.470, 35.717, 37.977, 42.828, and 46.938.

[0012] The X-ray powder diffraction pattern of crystal form A of the compound represented by formula II provided in this disclosure is as follows: Figure 2 As shown.

[0013] The present disclosure provides a crystal form A of the compound represented by Formula II, wherein the error range of the 2θ angle is ±0.2.

[0014] This disclosure further provides a method for preparing the A crystal form of the compound shown in Formula II, the method comprising: mixing the compound shown in Formula II with an appropriate amount of solvent and slurrying, separating the solid, wherein the solvent is an ether, preferably diethyl ether.

[0015] The crystal form obtained in this disclosure was subjected to structural determination and crystal form study by X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC).

[0016] The crystallization method of the crystal form disclosed herein is conventional, such as volatilization, cooling crystallization, or crystallization at room temperature.

[0017] The starting material used in the crystal form preparation method disclosed herein can be any form of the compound shown in Formula II, including but not limited to: amorphous, arbitrary crystal form, hydrate, solvate, etc.

[0018] This disclosure further provides a pharmaceutical composition comprising crystal form A of a compound of formula II, and one or more pharmaceutically acceptable carriers or excipients.

[0019] This disclosure further provides a pharmaceutical composition prepared by using the A crystal form of a compound of Formula II with one or more pharmaceutically acceptable carriers or excipients.

[0020] This disclosure further provides a method for preparing a pharmaceutical composition, comprising the step of mixing the A crystal form of a compound represented by Formula II with one or more pharmaceutically acceptable carriers or excipients.

[0021] This disclosure further provides the use of the A crystal form of the compound shown in Formula II, or the composition prepared by the aforementioned method, in the preparation of a medicament for treating physiological disorders, symptoms, or diseases in patients, wherein the physiological disorders, symptoms, or diseases are preferably respiratory diseases, cough, inflammatory diseases, skin disorders, ophthalmic disorders, depression, anxiety, phobias, bipolar disorder, alcohol dependence, substance abuse with significant neurological effects, epilepsy, nociceptive disorders, psychosis, schizophrenia, Alzheimer's disease, dementia associated with AIDs, Towne's disease, stress-related disorders, obsessive-compulsive disorder, bulemia, anorexia nervosa, binge eating, mania, premenstrual syndrome, gastrointestinal dysfunction, atherosclerosis, fibrotic disorders, obesity, type II diabetes, headache, neuropathic pain, post-movement pain, chronic pain syndrome, bladder disorders, genitourinary disorders, or vomiting or nausea.

[0022] In the specification and claims of this application, unless otherwise stated, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. However, for a better understanding of this disclosure, definitions and explanations of some related terms are provided below. Furthermore, in the event of any discrepancy between the definitions and explanations of terms provided herein and their commonly understood meanings by those skilled in the art, the definitions and explanations provided herein shall prevail.

[0023] The “X-ray powder diffraction pattern or XRPD” described in this disclosure refers to the X-ray powder diffraction pattern obtained when X-rays are incident on an atomic surface of a crystal or part of a crystal sample with a lattice spacing of d at a grazing angle θ (the complementary angle of the incident angle, also known as the Bragg angle) with a grazing angle θ.

[0024] The “X-ray powder diffraction pattern or XRPD” described in this disclosure is a pattern obtained by using Cu-Kα radiation in an X-ray powder diffractometer.

[0025] The “differential scanning calorimetry or DSC” described in this disclosure refers to measuring the temperature difference and heat flow difference between the sample and the reference material during the sample heating or isothermal process, in order to characterize all physical and chemical changes related to thermal effects and obtain phase transition information of the sample.

[0026] The "thermogravimetric analysis or TGA" as described in this disclosure refers to the continuous measurement of the change in the mass of a sample with temperature or time under programmed temperature control.

[0027] The “2θ or 2θ angle” mentioned in this disclosure refers to the diffraction angle, where θ is the Bragg angle, and the unit is ° or degree. The error range of 2θ is ±0.3 or ±0.2 or ±0.1.

[0028] The "interplanar spacing or interplanar spacing (d-value)" described in this disclosure refers to the use of three non-parallel unit vectors a, b, and c to connect adjacent lattice points in a space lattice. These vectors divide the lattice into juxtaposed parallelepiped units, known as the interplanar spacing. The space lattice is divided according to these defined parallelepiped unit lines, resulting in a linear grid called a space lattice or crystal lattice. Lattices and crystal lattices respectively use geometric points and lines to reflect the periodicity of a crystal structure. Different crystal planes have different interplanar spacings (i.e., the distance between two adjacent parallel crystal planes); the unit is d / d. Or E. Attached Figure Description

[0029] Figure 1 The XRPD pattern of the amorphous compound shown in Formula II is shown below.

[0030] Figure 2 The XRPD pattern of compound A, as shown in Formula II, is shown.

[0031] Figure 3 The DSC spectrum of compound A, as shown in Formula II, is shown.

[0032] Figure 4 The TGA spectrum of compound A, as shown in Formula II, is shown. Detailed Implementation

[0033] The present disclosure will be explained in more detail below with reference to the embodiments. The embodiments of the present disclosure are only used to illustrate the technical solutions of the present disclosure and are not intended to limit the substance and scope of the present disclosure.

[0034] Test conditions for the instruments used in the experiment:

[0035] 1. Differential Scanning Calorimeter (DSC)

[0036] Instrument model: Mettler Toledo DSC 3+

[0037] Purge gas: Nitrogen, 50 mL / min

[0038] Heating rate: 10.0℃ / min

[0039] Temperature range: 25-300℃

[0040] 2. X-ray Powder Diffraction (XRPD)

[0041] Instrument Model: BRUKER D8 DISCOVER

[0042] Radiation: Monochromatic Cu-Kα radiation (Cu-Kα1 wavelength is...) The wavelength of Cu-Kα2 is The Cu-Kα wavelength is taken as the weighted average of Kα1 and Kα2. )

[0043] Scanning mode: θ / 2θ, scanning range: 3-50°

[0044] Voltage: 40KV, Current: 40mA

[0045] 3. Thermogravimetric Analysis (TGA)

[0046] Instrument Model: METTLER TOLEDO TGA 2

[0047] Purge gas: Nitrogen, 50 mL / min

[0048] Heating rate: 10.0℃ / min

[0049] Temperature range: 25-350℃

[0050] The structure of the compound was determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). NMR shifts (δ) were expressed in 10⁻¹⁰. -6 The unit (ppm) is given. NMR measurements were performed using a Bruker AVANCE-400 NMR spectrometer. The solvents used were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), and deuterated methanol (CD3OD), with tetramethylsilane (TMS) as the internal standard.

[0051] MS measurements were performed using a Finnigan LCQAd(ESI) mass spectrometer (manufacturer: Thermo, model: Finnigan LCQadvantage MAX).

[0052] High-performance liquid chromatography (HPLC) analysis was performed using an Agilent HPLC 1200DAD, an Agilent HPLC 1200VWD, and a Waters HPLC e2695-2489 high-performance liquid chromatograph.

[0053] Chiral HPLC analysis was performed using an Agilent 1260DAD high-performance liquid chromatograph.

[0054] High performance liquid chromatography (HPLC) was performed using Waters 2767, Waters 2767-SQ Detecor2, Shimadzu LC-20AP, and Gilson-281 preparative chromatographs.

[0055] Chiral preparation was performed using a Shimadzu LC-20AP preparative chromatograph.

[0056] The CombiFlash rapid preparation system uses a CombiFlash Rf200 (TELEDYNE ISCO).

[0057] Thin-layer chromatography silica gel plates are Yantai Huanghai HSGF254 or Qingdao GF254. The silica gel plates used in thin-layer chromatography (TLC) have a diameter of 0.15 mm to 0.2 mm, and the diameter of the silica gel plates used for thin-layer chromatography separation and purification products is 0.4 mm to 0.5 mm.

[0058] Silica gel column chromatography generally uses Yantai Huanghai silica gel with a mesh size of 200-300 as the carrier.

[0059] The known starting materials disclosed herein can be synthesized using or in accordance with methods known in the art, or can be purchased from companies such as ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, AccelaChemBio Inc, and Darui Chemicals.

[0060] Unless otherwise specified in the examples, the reactions can be carried out under an argon or nitrogen atmosphere.

[0061] Argon or nitrogen atmosphere refers to a reaction flask connected to an argon or nitrogen gas balloon with a volume of approximately 1L.

[0062] A hydrogen atmosphere refers to a reaction flask connected to a hydrogen balloon with a volume of approximately 1L.

[0063] The pressurized hydrogenation reaction was performed using a Parr 3916EKX hydrogenator and a Qinglan QL-500 hydrogen generator or an HC2-SS hydrogenator.

[0064] The hydrogenation reaction is usually carried out under vacuum, filled with hydrogen gas, and repeated 3 times.

[0065] The microwave reaction was performed using a CEM Discover-S 908860 microwave reactor.

[0066] Unless otherwise specified in the examples, "solution" refers to an aqueous solution.

[0067] Unless otherwise specified in the examples, the reaction temperature is room temperature, which is 20℃~30℃.

[0068] The reaction process in the examples was monitored using thin-layer chromatography (TLC). The developing solvent used in the reaction, the eluent system used for column chromatography to purify the compounds, and the developing solvent system for TLC included: A: n-hexane / ethyl acetate system, B: dichloromethane / methanol system. The volume ratio of the solvent was adjusted according to the polarity of the compounds, and small amounts of basic or acidic reagents such as triethylamine and acetic acid could also be added for adjustment.

[0069] Example 1: Preparation of Compound II

[0070]

[0071] first step:

[0072]

[0073] Under N2 protection, compound 1 (2.43 g, 4.86 mmol, 1 eq) was weighed into a 100 mL three-necked flask and dissolved in dichloromethane (36 mL). Diisopropylethylamine (5 g, 38.76 mmol, 8 eq) was added, and the mixture was cooled to -30 °C. Trimethylchlorosilane (1.36 g, 12.52 mmol, 2.6 eq) was added, and the mixture was stirred at room temperature for 2 h. The mixture was then cooled to -25 °C, and a dichloromethane solution of methyl chloroformate (0.77 g, 6 mmol, 1.23 eq) was added dropwise. The mixture was stirred at -20 °C to -5 °C until the reaction was complete. The reaction mixture was poured into ice water, separated, extracted with dichloromethane, and then separated again with water and 1 N hydrochloric acid solution. The mixture was washed successively with brine, saturated sodium bicarbonate aqueous solution, and brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain 3.0 g of a yellow gelatinous substance, with a yield of 104%.

[0074] Step Two:

[0075]

[0076] Under N2 protection, compound 2 (2.8 g, 4.53 mmol, 1 eq), tetrabutylammonium iodide (1.68 g, 4.55 mmol, 1 eq), potassium di-tert-butyl phosphate (5.63 g, 22.67 mmol, 5 eq), and dioxane (84 mL) were added to a 500 mL three-necked flask. The mixture was heated to 55 °C and stirred for 4 h. The reaction solution was cooled, poured into ethyl acetate and water, separated, extracted with ethyl acetate, washed with an aqueous solution of sodium sulfite, then washed successively with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give 3.73 g of yellow foam, yield 107%.

[0077] Step 3:

[0078]

[0079] Under N2 protection, compound 3 (6.65 g, 8.67 mmol, 1 eq) was dissolved in dichloromethane (200 mL) in a 500 mL single-necked flask. Trifluoroacetic acid (9.89 g, 86.7 mmol, 10.0 eq) was slowly added under ice water cooling. The mixture was stirred until the reaction was complete, concentrated, and 2.29 g of oil was obtained. The oil was purified by reverse-phase silica gel column chromatography (C18) (solution A: 20 mmol NH4HCO3 aqueous solution, solution B: acetonitrile). The pH was adjusted to 1-2 with 1 M phosphoric acid, extracted with dichloromethane, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain 2.7 g of the target product.

[0080] 1 H-NMR (400MHz, CD3OD): δ (ppm) 7.89 (s, 2H), 7.86 (s, 1H), 7.41-7.27 (m, 5H), 5.66 (d, J=12Hz, 1H), 5.50-5. 47 (m, 1H), 4.60 (d, J=8Hz, 1H), 4.20-3.88 (m, 3H), 2.51-2.10 (m, 5H), 1.86-1.66 (m, 3H), 1.44-1.31 (m, 4H).

[0081] X-ray powder diffraction analysis showed that compound 4 (i.e., the compound shown in formula II) is amorphous, and its XRPD spectrum is as follows. Figure 1 .

[0082] Test Example 1: Solubility

[0083] 1.1 Preparation of reagents

[0084] Reagent: NaH2PO4·2H2O

[0085] 1.2 Preparation method

[0086] Prepare as follows for 100ml:

[0087] pH=3.0: Phosphate buffer solution: 100ml 20mmol / L NaH2PO4, 0.1M H3PO4 to adjust pH to 3.0.

[0088] pH=4.0: Phosphate buffer solution: 100ml 20mmol / L NaH2PO4, 0.1M H3PO4 to adjust pH to 4.0.

[0089] pH = 7.0: Ultrapure water

[0090] pH = 9.0: Phosphate buffer solution: 100 ml 20 mmol / L Na₂HPO₄, 0.1 M NaOH solution. Adjust pH to 9.0.

[0091] 1.3 Test Methods

[0092] Accurately weigh an appropriate amount of the compound from Example 1, add it to the solution in small amounts several times while stirring and waiting for the compound to dissolve, and determine the content of the compound in the solution. The data are shown in Table 1.

[0093] Table 1

[0094] pH solubility Saturated solubility 7.4 26mg / ml 19.8mg / ml 9.0 28mg / ml 21.4 mg / ml

[0095] Test Example 2: Hemolysis

[0096] Red blood cells (RBCs) were randomly collected (10 ml of EDTA-treated whole blood) from the jugular vein or central auricular artery of rabbits and placed in a triangular flask containing glass beads. The flask was shaken for 10 minutes to remove fibrinogen, resulting in defibrinated blood. Approximately 10 times the volume of sodium chloride injection solution was added, and the mixture was shaken well. The mixture was centrifuged at 1500 rpm for 10 minutes, and the supernatant was removed. The precipitated red blood cells were washed three times with sodium chloride injection solution as described above until the supernatant no longer appeared red. The obtained red blood cells were then resuspended in sodium chloride injection solution to prepare a 2% (v / v) suspension for later use.

[0097] Dissolve the compound from Example 1 in PBS (pH 7.4 or pH 5), filter, and prepare concentrations of 0.4 mg / ml, 0.8 mg / ml, 1.2 mg / ml, 1.6 mg / ml, and 2 mg / ml for later use.

[0098] A certain amount of the compound solution from Example 1 was added to the hemoglobin and tested in the supernatant.

[0099] If the solution in the test tube is clear red, with no cells or only a small number of red blood cells remaining at the bottom, it indicates that hemolysis has occurred. If all the red blood cells have settled and the supernatant is colorless and clear, it indicates that no hemolysis has occurred. If there is a brownish-red or reddish-brown flocculent precipitate in the solution that does not disperse even after being gently inverted 3-5 times, it indicates that red blood cell aggregation may have occurred; further observation under a microscope is necessary, and if red blood cell aggregation is visible, it indicates aggregation. The compound provided in this disclosure is used to determine hemolysis using this method.

[0100] Conclusion: The compound in Example 1 did not exhibit hemolytic activity at concentrations up to 2 mg / ml.

[0101] Test Example 3: Hemolytic Effect of Lorapitane Emulsion

[0102] Lorapistane emulsion (formulation: 4.4% polyethylene glycol-15-hydroxystearate, 1.1% medium-chain triglycerides and 0.66% soybean oil) was prepared according to the method in CN102573475, and 0.18 mg / ml, 0.09 mg / ml, 0.045 mg / ml, 0.023 mg / ml, 0.011 mg / ml, 0.056 mg / ml and 0.028 mg / ml were prepared with PBS for later use.

[0103] The hemolytic effect was determined according to the method in Test Example 2.

[0104] Conclusion: All concentrations of rorapitant emulsion exhibit hemolytic activity.

[0105] Test Example 4: Pharmacokinetic Test in Crab-Eating Mammals

[0106] Using cynomolgus monkeys as test animals, the plasma drug concentration at different time points after injection administration of the compound prepared according to the method in Example 1 was determined by LC / MS / MS. The pharmacokinetic behavior of this compound in cynomolgus monkeys was studied to evaluate its pharmacokinetic characteristics.

[0107] Drug preparation

[0108] Weigh a certain amount of the compound to be tested and prepare a solution with pH=4.0 using 20mmol / L sodium dihydrogen phosphate for later use.

[0109] 1.1 Administration

[0110] Administered via intravenous drip, with a bolus injection time of approximately 30 minutes. The dosage is 3.54 mg / kg, the concentration is 2 mg / ml, and the volume is 5 ml / kg.

[0111] 1.2 Operation

[0112] Blood samples were collected via the femoral vein before administration and at 5 min, 0.25 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, and 24 h after administration. Approximately 0.6 mL of each sample was collected. Heparin sodium was used for anticoagulation, and the samples were immediately placed on ice after collection. After collection, the blood samples were placed in labeled centrifuge tubes, and plasma was separated by centrifugation (centrifugation conditions: centrifugation force 2200 g, centrifugation for 10 min, 2-8℃).

[0113] The contents of the compound from Example 1 and rorapitane in plasma samples were determined by LC / MS / MS.

[0114] 1.3 Pharmacokinetic Parameter Results

[0115] Table 2

[0116]

[0117] Note: a) Pharmacokinetic parameters of the compound in cynomolgus monkeys in example b) and pharmacokinetic parameters of the compound metabolized into rorapitan in cynomolgus monkeys in example b.

[0118] Conclusion: In the pharmacokinetic study of cynomolgus monkeys, the compound was rapidly converted into the active metabolite rorapitan in the majority of the monkeys, exhibiting good pharmacokinetic properties.

[0119] Example 2: Preparation of crystal form A of compound II

[0120] Weigh approximately 100 mg of the compound shown in Formula II, add it to 1 mL of diethyl ether, stir at room temperature until dissolved, slurry to precipitate the solid, centrifuge, and then vacuum dry to obtain crystal form A of the compound shown in Formula II. The positions of its characteristic peaks are shown in Table 3.

[0121] Table 3: XRD characteristic peak positions of crystal form A

[0122]

[0123]

[0124] Example 3: Stability study of crystal form A

[0125] The stability of compound A of formula II was investigated by placing it at 4°C.

[0126] Table 4

[0127]

[0128] The results showed that crystal form A exhibited good physical and chemical stability after being placed at 4℃ for 3 months.

Claims

1. A crystal form of the compound shown in Formula II, Its X-ray powder diffraction pattern has characteristic peaks at 2θ angles of 10.336, 12.530, 17.987, 18.487, and 20.

937.

2. The A crystal form of the compound shown in Formula II according to claim 1 has characteristic peaks in its X-ray powder diffraction pattern at 2θ angles of 10.336, 11.705, 12.530, 16.848, 17.987, 18.487, 19.840, 20.937, 22.865, and 23.

580.

3. The A-type crystal form of the compound shown in Formula II according to claim 2, wherein the X-ray powder diffraction pattern is at 2θ angles of 8.367, 10.336, 11.150, 11.705, 12.530, 13.306, 14.236, 15.252, 16.330, 16.848, 17.459, 17.987, 18.487, 19. Characteristic peaks are found at 294, 19.840, 20.937, 21.963, 22.285, 22.865, 23.580, 24.812, 25.961, 26.798, 27.597, 28.761, 29.784, 31.737, 32.470, 35.717, 37.977, 42.828, and 46.

938.

4. The X-ray powder diffraction pattern of the compound of formula II according to claim 1 is shown in Figure 2.

5. The A crystal form of the compound of formula II according to any one of claims 1-4, wherein the error range of the 2θ angle is ±0.

2.

6. A process for preparing the crystalline form A of the compound of formula II according to any one of claims 1 to 5, which process comprises: The compound shown in Formula II is mixed with an appropriate amount of solvent and pulped to separate the solid. The solvent is an ether.

7. The method according to claim 6, wherein the solvent is diethyl ether.

8. A pharmaceutical composition comprising crystal form A of the compound of formula II as claimed in any one of claims 1-5, and one or more pharmaceutically acceptable carriers or excipients.

9. A pharmaceutical composition prepared by reacting the A crystal form of a compound of formula II as described in any one of claims 1-5 with one or more pharmaceutically acceptable carriers or excipients.

10. A method for preparing a pharmaceutical composition, comprising the step of mixing the A crystal form of the compound of formula II as described in any one of claims 1-5 with one or more pharmaceutically acceptable carriers or excipients.

11. The use of the A crystal form of the compound of formula II according to any one of claims 1-5, or the use of the composition according to any one of claims 8-9 in the preparation of a medicament for treating a patient's disease, said disease being selected from respiratory diseases, inflammatory diseases, skin disorders, ophthalmic disorders, depression, anxiety, phobias, bipolar disorder, alcohol dependence, epilepsy, psychosis, Alzheimer's disease, dementia associated with AIDs, stress-related disorders, obsessive-compulsive disorder, anorexia nervosa, mania, premenstrual syndrome, gastrointestinal dysfunction, atherosclerosis, fibrotic disorders, obesity, type II diabetes, headache, neuropathic pain, chronic pain syndrome, bladder disorders, genitourinary disorders, or vomiting or nausea.

Citation Information

Patent Citations

  • Neurokinin-1 antagonist

    WO2020259675A1